<DOC>
	<DOCNO>NCT01219140</DOCNO>
	<brief_summary>Treatment post-menopausal subject ( decrease bone mineral density ) pomegranate extract capsule produce statistically significant change biomarkers bone resorption formation compare subject receive placebo .</brief_summary>
	<brief_title>Pomegranate Extract Biomarker Study Osteopenic Women</brief_title>
	<detailed_description />
	<criteria>Postmenopausal woman ( last menstrual period within past 15 year appropriate serum FSH value ) 4565 year age ; The subject must T score 1 2.5 lumbar spine proximal femur ; All clinical safety laboratory value screen randomization must either within reference range determine investigator sponsor abnormal , clinically significant ; The patient must provide write informed consent . The subject follow condition : connective tissue disease , history clinically significant renal , hepatic pulmonary , cardiovascular , cerebrovascular , gastrointestinal , metabolic , hematological , endocrinological , urological , immunological , neurologic psychiatric disorder , unless approve sponsor case case basis ; The subject positive test result Hepatitis B surface antigen antibody hepatitis C virus Screening ; The subject know history infection human immunodeficiency virus ( HIV ) ; The subject use bisphosphonate fluoride therapy within past 12 24 month , respectively ; The subject use denosumab within past 24 month ; The subject use tibolone , parathyroid hormone ( derivative ) , systemic glucocorticoid inhale glucocorticoid , anabolic steroid testosterone within past 6 month ; The subject use estrogen , selective estrogen receptor modulators , calcitonin calcitriol within past 3 month ; The subject hyperparathyroidism , hypoparathyroidsim , hyperthyroidism , hypothyroidism , hypocalcemia , rheumatoid arthritis , paget 's disease bone , osteomalacia ; The subject bone fracture within past year ; The subject acute chronic disease require frequent change medication dosage chronic therapy ; A history alcoholism within last 2 year current history imbibe 3 unit alcohol per day . ( 1 unit equivalent 1 glass wine , 1 pint beer , 1 shot hard liquor ) ; The subject participate another study investigational drug device 30 day prior study entry ; The subject condition interfere ability provide inform consent comply study instruction , patient condition , might confound interpretation study result ; The subject condition endanger participate trial</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>POMx</keyword>
	<keyword>Osteopenia</keyword>
	<keyword>postmenopausal woman</keyword>
	<keyword>Pomegranate</keyword>
</DOC>